ACADIA Pharmaceuticals Inc
Analyzing IBB’s Moving Averages
As of June 13, 33% of IBB’s stocks were trading above their 20-day moving averages and 43% were trading above their 50-day moving averages.
Opko Health: Q2 Expenditures, Developments, Recommendations
Opko Health’s (OPK) cost of revenues declined from $157.4 million in Q2 2017 to $150.1 million in Q2 2018.
IMMU and ACRX Outperform in the Biotech Downdraft
Immunomedics (IMMU) rose by 13% on October 6, 2015. The stock rose on buying support with good trade volumes. The stock closed at $2.08.
Alnylam Pharmaceuticals Initiates Phase 1 Trial of ALN-TTRsc02
Alnylam Pharmaceuticals (ALNY) was one of the most underperforming biotech stocks for the week ended June 10, 2016. It fell 10% due to profit booking.
Acadia Pharma Moves Up on FDA Approval
Today, Acadia Pharmaceuticals (ACAD) is trending higher on news of the FDA’s approval of a 34 mg capsule and 10 mg tablet of Nuplazid (pimavanserin) for patients with Parkinson’s disease psychosis-related hallucinations and delusions.
ANAC Leads Pharmaceuticals Valuations in the Week Ending July 17
Anacor Pharmaceuticals (ANAC) with a 71.92% jump in its price for the week ending July 17, 2015, has helped to push the average PVB of the pharmaceutical sector to 11.62.
Biotechnology ETFs: Who Were the Top Performers Last Week?
Biotechnology ETFs rose during the week ending April 1, 2016. The SPDR S&P Biotech ETF (XBI) and the iShares NASDAQ Biotechnology ETF (IBB) rose 6.2% and 5.0%, respectively.
Anacor Stayed Positive among the Hammered Mid-Caps
Anacor Pharmaceuticals (ANAC) was one of the top mid-cap performers for the week. It rose by 5.9% for the week. The stock rose due to good trading volumes.
Why Is Acadia Pharmaceuticals Falling Today?
Yesterday, Acadia Pharmaceuticals reported top-line results from its phase three trial evaluating Nuplazid in schizophrenia.
Spectrum Pharmaceuticals: Earnings Trends and Recent Developments
In the first nine months of 2018, Spectrum Pharmaceuticals reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively.
Spectrum Pharmaceuticals: Financial Overview in December
In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY to $79.9 million from $99.8 million.
Why Acadia Pharmaceuticals Stock Rose 20.8% Yesterday
On November 28, Acadia Pharmaceuticals stock closed at $20.53, which represents a ~20.76% rise from its close of $17.00 on November 27.
A Look at Portola Pharmaceuticals’ Financial Performance
Portola Pharmaceuticals’ (PTLA) net revenues grew from $3.79 million in the second quarter of 2017 to $4.01 million in the second quarter of 2018.
Look at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.
Analyzing Axovant Sciences’ Valuation Metrics
In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given it a “buy” rating, and five have given it a “hold.”
How Opko Health Fared in the Second Quarter of 2018
Opko Health (OPK) generated net revenues of $263.7 million in the second quarter of 2018 compared to $292.6 million in Q2 of 2017.
Exploring Acadia Pharmaceuticals’ Promising Research Pipeline
Acadia Pharmaceuticals’ Nuplazid is commercialized in the US market for the treatment of hallucinations and delusions related to Parkinson’s disease psychosis.
What Analysts Thought of Ligand Pharmaceuticals in June
Two of the six analysts covering Ligand Pharmaceuticals in June gave the stock “strong buy” ratings, and four gave it “buy” ratings.
Why Axovant Sciences Stock Rose in Week Ended June 8
On June 6, Axovant Sciences entered into an agreement to develop and sell Oxford BioMedica’s OXB-102 for the treatment of Parkinson’s disease.
Nuplazid for Long-Term Care: Revenue Driver for Acadia?
Acadia Pharmaceuticals (ACAD) plans to focus on long-term care (or LTC) facilities to boost Nuplazid’s adoption in the Parkinson’s disease (or PD) psychosis indication.
Nuplazid Sees Increasing Physician Intent to Prescribe in 2017
Acadia Pharmaceuticals’ (ACAD) commercial teams have been carrying out promotional efforts to create awareness for Nuplazid among physicians with the intent to have them prescribe the drug.
Nuplazid Expected to Become a Leading Central Nervous System Drug
On April 29, 2016, the FDA approved Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) as a first therapy for treating patients with Parkinson’s disease (or PD) psychosis.
What Analysts Recommend for Acadia Pharmaceuticals in September
Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”
XBI’s Holdings: What’s the Trend in Its Moving Averages?
On June 15, 2016, XBI closed at $54.74. It was trading above its 20-day and 50-day moving averages. XBI’s 20-day moving average is $56.30.
Investors Not Impressed with Immunomedics’ IMMU-132 Study
On June 6, 2016, biotech stocks continued their upward trend and appeared to be in a positive, consolidating mood. IBB rose 1.5% that day.
Analyst Estimates for Ionis Pharmaceuticals’ 2016 Revenue
Analyst estimates show Ionis Pharmaceuticals’ 2016 revenue at $237 million. That’s a decline of more than 16% compared to $284 million for 2015.
Mid-Cap News: Intercept Rose on Accelerated Approval of Ocaliva
Intercept Pharmaceuticals (ICPT) rose 19.6% for the week ended April 8, 2016. It closed at $156.36 and was trading above its 20-day and 100-day moving averages
Incyte Continues Its Growth Spree in 2015
Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.
Anacor Pharmaceuticals: $250 Million in Convertible Senior Notes
Anacor Pharmaceuticals rose 7.8% and closed at $61.51 on April 4, 2016. It was trading above its 20-day moving average. Year-to-date, the stock has fallen 45.6%.
XBI Mid-Cap News: Look Who Took a Beating on March 23
Among the 18 mid-cap stocks that XBI holds in its portfolio, 17 declined and only one advanced on March 23. Mid-caps represent ~30% of XBI’s portfolio.
ISIS Leads the Mid-Cap Space, Stock Rises by 12.3%
ISIS Pharmaceuticals rose by 12.3% as it announced 3Q15 earnings. ISIS reported revenue of $49.1 million as compared to $44.1 million in 3Q14.
Myriad Genetics: Top Performer in the Biotechnology Subgroup
Myriad Genetics (MYGN) rose 9% on November 4, 2015. It reported its fiscal 1Q16 results. Myriad Genetics reported revenue of $183.5 million.
XBI’s Top Ten Small-Cap Stocks Perform on Par with Large-Caps
In the small-cap space, the top ten stocks of XBI had an average return of -12.18% for the week ended September 25, 2015. This is similar to XBI’s top ten large-cap stocks that returned -12.15%.
ENDP Traded above 100-Day Moving Average in Week to September 18
ENDO International (ENDP) rose 9.52%. The stock went up on high trading volumes during September 16-18.
Dyax Traded above Its 100-Day Moving Average
Dyax (DYAX) gained 9.41% last week. The stock went up after Dyax presented at the Morgan Stanley global healthcare conference, which took place September 16-18 in New York.
XBI Stocks: 33% Are Trading above the 20-Day Moving Averages
XBI fell substantially in the moving averages. From August 10–17, 2015, only 32.63% of the stocks were trading above the 20-day moving averages.
Pharmaceutical Stocks Affect the iShares NASDAQ Biotechnology ETF
Out of 62 stocks held within the pharmaceutical subgroup of the iShares NASDAQ Biotechnology ETF (IBB), 49 stocks fell during the week ending August 7, 2015.
IBB ETF Pounded by Biotech and Pharma Subgroups in Early August
The biotechnology and pharmaceutical subgroups comprise 97.43% of the iShares NASDAQ Biotechnology ETF (IBB) portfolio.
Anacor Pharmaceuticals Outperforms the Market
Within IBB, stocks like Receptos and Celgene performed well. However, Anacor Pharmaceuticals outperformed everyone with an eye-catching 71.92% for the week ending July 17.